Company news
Vivani Medical, Inc. news in 2024
Vivani Medical, Inc.'s news releases, calls and decks from 2024, newest first.
Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
December 18, 2024
Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast
December 3, 2024
Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results
November 12, 2024
Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024
October 21, 2024
Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
September 25, 2024
Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024
September 22, 2024
Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant
September 3, 2024
Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
August 27, 2024
Vivani Medical Provides Business Update and Reports Second Quarter 2024 Financial Results
August 12, 2024
Vivani Medical Provides Update on Clinical Development Plans for Miniature, Long-term, GLP-1 Obesity Implant Program, NPM-115
July 10, 2024
Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant
June 12, 2024
Vivani Medical Announces Publication of Positive Weight Loss Data Supporting Potential Veterinary Use of OKV-119 Miniature, Long-term GLP-1 Implant
May 27, 2024
Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results
May 12, 2024
Vivani Medical to Present at TIDES Conference 2024
May 8, 2024
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
March 25, 2024
Vivani Medical Appoints Daniel Bradbury to its Board of Directors
March 5, 2024
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
February 29, 2024
Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio
February 27, 2024
Decks in 2024
- Q3 2024 Earnings Presentation
Earnings · 33 slides · Nov 13, 2024
- Q2 2024 Earnings Presentation
Earnings · 33 slides · Aug 13, 2024
- Investor Presentation (May 2024)
Investor deck · 34 slides · May 13, 2024
- Investor Presentation (March 2024)
Investor deck · 34 slides · Mar 26, 2024
- Investor Presentation (February 2024)
Investor deck · 34 slides · Feb 28, 2024